{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:43:33Z","timestamp":1793868213398,"version":"4.6.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,2]],"date-time":"2027-07-02T00:00:00Z","timestamp":1814486400000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","award":["R37CA288448"],"award-info":[{"award-number":["R37CA288448"]}],"id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","award":["R01CA285454"],"award-info":[{"award-number":["R01CA285454"]}],"id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","award":["RA230062"],"award-info":[{"award-number":["RA230062"]}],"id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","award":["KC200096P1"],"award-info":[{"award-number":["KC200096P1"]}],"id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200669"],"award-info":[{"award-number":["RP200669"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022084","name":"Peter MacCallum Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002163","name":"Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1122347"],"award-info":[{"award-number":["APP1122347"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eururo.2026.03.024","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:53:06Z","timestamp":1777319586000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5115-1691","authenticated-orcid":false,"given":"Alexander D.","family":"Sherry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Criselle","family":"D\u2019souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Kiany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niko","family":"Thio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieko","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan B.","family":"Ludmir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Neeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Haymaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.03.024_b0005","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jamaoncol.2023.7266","article-title":"Charting the path to systemic therapy de-escalation-oligometastatic kidney cancer as a paradigm","volume":"10","author":"Tang","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.03.024_b0010","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic ablative radiation for systemic therapy\u2013na\u00efve oligometastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.03.024_b0015","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.03.024_b0020","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(16)30196-6","article-title":"Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.03.024_b0025","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S1470-2045(25)00380-8","article-title":"Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial","volume":"26","author":"Tang","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.03.024_b0030","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.03.024_b0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.024_b0040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PPO.0000000000000750","article-title":"Current state of stereotactic body radiation therapy for genitourinary malignancies","volume":"30","author":"Sherry","year":"2024","journal-title":"Cancer J"},{"key":"10.1016\/j.eururo.2026.03.024_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100703","article-title":"A phase I\/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): clinical trial protocol","volume":"21","author":"Pryor","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.eururo.2026.03.024_b0050","doi-asserted-by":"crossref","first-page":"271.e1","DOI":"10.1016\/j.clgc.2020.08.003","article-title":"Causal diagram techniques for urologic oncology research","volume":"19","author":"Shapiro","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.03.024_b0055","first-page":"1887","article-title":"Robust causal inference using directed acyclic graphs: the R package 'dagitty'","volume":"45","author":"Textor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.eururo.2026.03.024_b0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urolonc.2024.10.022","article-title":"Impact of postprogression therapies on overall survival: recommendations from the 2023 kidney cancer association think tank meeting","volume":"43","author":"Berg","year":"2025","journal-title":"Urol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:37:21Z","timestamp":1783017441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826020592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0302283826020592"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.024","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}